stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Book value per share
Alkermes plc's book value per share at the end of fiscal 2025 was 11.0×, up 24.7% from 8.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 11.1×. Over the past ten years it has ranged from 6.4× (fiscal 2022) to 11.0× (fiscal 2025) — the current reading is the highest in ten years. Alkermes plc ranks 14th of 84 Drug Manufacturers Specialty & Generic companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 11.0× | 24.71% |
| FY2024 | 8.9× | 22.42% |
| FY2023 | 7.2× | 13.51% |
| FY2022 | 6.4× | (7.79%) |
| FY2021 | 6.9× | 2.89% |
| FY2020 | 6.7× | (2.79%) |
| FY2019 | 6.9× | (8.47%) |
| FY2018 | 7.6× | (3.69%) |
| FY2017 | 7.8× | (1.80%) |
| FY2016 | 8.0× | (9.36%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 11.1× | 2.59% |
| Jun 2026 | 10.8× | 2.74% |
| Mar 2026 | 10.5× | (4.59%) |
| Dec 2025 | 11.0× | 5.20% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | 20.8× |
| ELAN Elanco Animal Health Incorporated compare | 13.2× |
| ALKS Alkermes plc | 11.1× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 9.1× |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.9× |
| LQDA Liquidia Corporation compare | 2.2× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 1.6× |
| HIMS Hims & Hers Health, Inc. compare | 1.4× |
| SUPN Indivior Pharmaceuticals Inc. compare | −0.5× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ALKS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement